AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 08:00 am ET
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the AMAG Pharmaceuticals Second Quarter 2020 Earnings Call. [Operator Instructions] It is now my pleasure to turn today's call over to Ms. Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations. You may begin your conference.
Thank you, Regina. Good morning, and welcome to the AMAG Pharmaceuticals conference call to discuss our second quarter 2020 financial results. Earlier this morning, we issued a press release. For those of you who don't have a copy, you can access it in the Investors section of our website at www.amagpharma.com. Please be reminded that remarks made during this call may include forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Please refer to our 2019 Form 10-K, our Form 10-Qs and eight-Ks, including our upcoming Form 10-Q for the quarter ended June 30, 2020 as well as statements included in our presentation materials, for a full review of the risks and uncertainties associated with our business.
On today's call, we will discuss certain non-GAAP financial measures with respect to our performance. We use these non-GAAP measures for financial and operational decision-making and as a means to evaluate our performance because we believe they better represent the ongoing economics of our business. The definitions of our non-GAAP measures are set forth in our earnings release, which was filed with the SEC today. Copies may be obtained at sec.gov and in the Investors section of our website. We are conducting today's earnings call with participants in different locations given the COVID-19 pandemic. So we ask that you please bear with us if there are any technical issues. We do have a team and process in place to handle issues should they arise
Today, we are focusing our prepared remarks on the progress we are making against our strategic evolution to become a focused biotech company. We will have comments from Scott Myers, our President and CEO, Tony Casciano, our Chief Operating Officer; and Brian Piekos, our Chief Financial Officer. After their brief upfront comments, we're looking forward to opening the line for Q&A. With that, I will turn the call over to Scott.
Scott D. Myers
Thanks, Rushmie. Good morning. And thanks to everyone for joining us today. Since our last call on May 11, we've been making a great deal of progress on key milestones, all the while managing the business through the COVID-19 pandemic. You can see some of the headway we've made recently here on this slide. We'll talk about these accomplishments throughout this morning's call. Our Board of Directors and executive team are fully committed to our company's evolution. It's an exciting time to be in AMAG and shape the future of this company and